CMB International Global Markets | Equity Research | Company Update

Xpeng Inc. (XPEV US/9868 HK)

Entered a virtuous circle

Maintain BUY. Xpeng's 1Q25 earnings beat on GPM and government subsidies. We further raise our FY25E sales volume and GPM forecasts given the current sales momentum and more new model rollouts in 2H25. We are of the view that Xpeng may achieve a breakeven at the net level in 3Q25. Such profit growth path has helped Xpeng enter a virtuous circle with more R&D investments and even higher profits, in our view.

- 1Q25 earnings beat on GPM and government subsidies. Xpeng's 1Q25 revenue beat our prior forecast by 1.7%, mainly due to higher-than-expected average selling price (ASP). Vehicle GPM of 10.5% in 1Q25 was in line with our forecast, while GPM for services and others was about 10ppts higher than our projection. SG&A and R&D expenses combined were about RMB180mn higher than expected, which was offset by higher government subsidies. Net loss of RMB664mn was about RMB260mn narrower than our forecast. Both operating loss and net loss excluding extraordinary items were largely in line with our prior forecasts.
- Improving profitability could support more new models and Al investments. We raise our FY25E sales volume forecast by 20,000 units to 460,000 units amid strong sales in the first four months of 2025 and more new model rollouts in 2H25. We revise up FY25E vehicle GPM from 11.3% to 12.0%, as new models with higher GPMs are to contribute more sales. We are of the view that it is possible for Xpeng to achieve a breakeven at the net level in 3Q25. A guidance of 32% YoY increase in R&D expenses in FY25E means a good number of new models could be unveiled in FY26E. Xpeng's proprietary Al chip plans to be equipped from 3Q25 means another big step forward in autonomous driving progress.
- Earnings/Valuation. We revise our FY25E net loss from RMB1.7bn to RMB0.9bn after raising sales volume and GPM forecasts. We also revise up FY26E GPM by 1.2ppts to 16.8%. We raise our FY26E net profit from RMB1.2bn to RMB3.7bn, by taking a possible tax credit into consideration. We maintain our BUY rating and ADR/H-share target price of US\$28.00/HK\$110, still based on 1.8x our FY26E P/S (unchanged). We think a valuation that is slightly higher than peers is justified given its leading AI capabilities and clearer profit growth path. Key risks to our rating and target price include lower sales volume and/or GPM than we expect, slower monetization timeline for robots and a sector de-rating.

Earnings Summary - XPEV US

(YE 31 Dec)	FY23A	FY24A	FY25E	FY26E	FY27E
Revenue (RMB mn)	30,676	40,866	86,862	109,437	126,942
YoY growth (%)	14.2	33.2	112.6	26.0	16.0
Gross margin (%)	1.5	14.3	16.1	16.8	16.7
Operating profit (RMB mn)	(10,889.4)	(6,658.1)	(2,608.5)	849.0	2,344.3
Net profit (RMB mn)	(10,375.8)	(5,790.3)	(907.2)	3,683.0	3,842.6
YoY growth (%)	na	na	na	na	4.3
EPS (Reported) (RMB cents)	(595.99)	(306.14)	(47.60)	191.76	198.52
P/S (x)	4.4	3.3	1.6	1.2	1.1
P/E (x)	ns	ns	ns	37.1	35.8
P/B (x)	3.4	4.3	4.4	3.9	3.5

Source: Company data, Bloomberg, CMBIGM estimates



	XPEV US	9868 HK
	BUY	BUY
	Maintain	Maintain
ТР	US\$28.00	HK\$110.00
Prior TP	US\$28.00	HK\$110.00
Up/Downside	42.2%	41.8%
Current Price	US\$19.7	HK\$77.6


China Auto

Ji SHI, CFA (852) 3761 8728 shiji@cmbi.com.hk

Wenjing DOU, CFA (852) 6939 4751

douwenjing@cmbi.com.hk

Austin Liang (852) 3900 0856 austinliang@cmbi.com.hk 12-mth Price Performance



	XPE	V US	9868 HK		
	Abs.	Rel.	Abs.	Rel.	
1-mth	8.2%	-1.4%	5.4%	-1.4%	
3-mth	7.0%	8.4%	7.9%	8.4%	
6-mth	60.2%	37.2%	63.8%	37.2%	

Stock Data	
------------	--

(LC)	XPEV US	9868 HK
Mkt Cap (mn)	18740.45	147380.1
Avg 3 mths t/o (mn)	159.93	2438.05
52w High	26.34	97.45
52w Low	6.63	26.05
Issued Shares (mn)	1903.55	1900.452
Source: FactSet		

Figure 1: Quarterly results



RMB mn	1Q24	2Q24	3Q24	4Q24	1Q25	YoY	QoQ
Sales volume (units)	21,821	30,207	46,533	91,507	94,008	330.8%	2.7%
ASP (RMB)	300,082	268,527	217,087	175,999	168,184	-44.0%	-4.4%
Revenue	6,548	8,111	10,102	16,105	15,811	141.5%	-1.8%
Gross profit	844	1,136	1,541	2,325	2,460	191.5%	5.8%
R&D expenses	(1,350)	(1,467)	(1,633)	(2,006)	(1,981)	46.7%	-1.3%
SG&A expenses	(1,388)	(1,574)	(1,633)	(2,275)	(1,946)	40.2%	-14.5%
Operating profit	(1,646)	(1,609)	(1,847)	(1,556)	(1,041)	N/A	N/A
Net profit	(1,368)	(1,285)	(1,808)	(1,330)	(664)	N/A	N/A
Gross margin	12.9%	14.0%	15.3%	14.4%	15.6%	2.7 ppts	1.1 ppts
Operating margin	-25.1%	-19.8%	-18.3%	-9.7%	-6.6%	18.5 ppts	3.1 ppts
Net margin	-20.9%	-15.8%	-17.9%	-8.3%	-4.2%	16.7 ppt	4.1 ppts

Source: Company data, CMBIGM

Figure 2: Earnings revision

		New			Old			Diff (%)	
RMB mn	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
Revenue	86,862	109,437	126,942	79,177	106,967	N/A	9.7%	2.3%	N/A
Gross profit	13,971	18,399	21,244	12,310	16,717	N/A	13.5%	10.1%	N/A
Operating profit	(2,609)	849	2,344	(3,010)	(483)	N/A	N/A	N/A	N/A
Net profit	(907)	3,683	3,843	(1,718)	1,229	N/A	N/A	199.7%	N/A
Gross margin	16.1%	16.8%	16.7%	15.5%	15.6%	N/A	0.5 ppts	1.2 ppts	N/A
Operating margin	-3.0%	0.8%	1.8%	-3.8%	-0.5%	N/A	0.8 ppts	1.2 ppts	N/A
Net margin	-1.0%	3.4%	3.0%	-2.2%	1.1%	N/A	1.1 ppts	2.2 ppts	N/A

Source: CMBIGM estimates

Figure 3: CMBI estimates vs consensus

		CMBIGM			Consensus	6		Diff (%)	
RMB mn	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
Revenue	86,862	109,437	126,942	82,661	114,462	139,421	5.1%	-4.4%	-9.0%
Gross profit	13,971	18,399	21,244	13,284	19,801	25,138	5.2%	-7.1%	-15.5%
Operating profit	(2,609)	849	2,344	(3,531)	621	4,018	N/A	36.7%	-41.6%
Net profit	(907)	3,683	3,843	(1,934)	2,382	5,865	N/A	54.6%	-34.5%
Gross margin	16.1%	16.8%	16.7%	16.1%	17.3%	18.0%	0.0 ppts	-0.5 ppts	-1.3 ppts
Operating margin	-3.0%	0.8%	1.8%	-4.3%	0.5%	2.9%	1.3 ppts	0.2 ppts	-1.0 ppts
Net margin	-1.0%	3.4%	3.0%	-2.3%	2.1%	4.2%	1.3 ppts	1.3 ppts	-1.2 ppts

Source: Bloomberg, CMBIGM estimates



Financial Summary

INCOME STATEMENT	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec (RMB mn)						
Revenue	26,855	30,676	40,866	86,862	109,437	126,942
Cost of goods sold	(23,767)	(30,225)	(35,021)	(72,891)	(91,038)	(105,698)
Gross profit	3,088	451	5,846	13,971	18,399	21,244
Operating expenses	(11,794)	(11,341)	(12,504)	(16,580)	(17,550)	(18,900)
SG&A expense	(6,688)	(6,559)	(6,871)	(9,180)	(9,550)	(10,900)
R&D expense	(5,215)	(5,277)	(6,457)	(8,400)	(9,500)	(10,000)
Others	109	495	823	1,000	1,500	2,000
Operating profit	(8,706)	(10,889)	(6,658)	(2,609)	849	2,344
Gain/loss on financial assets at FVTPL	84	(635)	(262)	230	0	0
Other gains/(losses)	(1,424)	139	59	250	150	150
EBITDA	(7,571)	(7,963)	(2,943)	2,313	6,120	8,115
Depreciation	915	1,646	1,572	2,063	2,394	2,646
Depreciation of ROU assets	379	182	413	275	285	295
Other amortisation	116	279	588	599	621	644
EBIT	(8,982)	(10,070)	(5,516)	(624)	2,820	4,531
Interest income	1,059	1,260	1,375	1,454	1,721	1,936
Interest expense	(132)	(269)	(344)	(283)	(190)	(164)
Pre-tax profit	(9,114)	(10,339)	(5,860)	(907)	2,631	4,367
Income tax	(25)	(37)	70	0	1,052	(524)
After tax profit	(9,139)	(10,376)	(5,790)	(907)	3,683	3,843
Others	0	0	0	0	0	0
Net profit	(9,139)	(10,376)	(5,790)	(907)	3,683	3,843
BALANCE SHEET	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec (RMB mn)						
Current assets	43,527	54,522	49,736	79,672	102,171	120,667
Cash & equivalents	14,608	21,127	18,586	29,232	40,196	53,204
Restricted cash	106	3,175	3,153	2,000	2,000	2,000
Account receivables	3,873	2,716	2,450	7,139	8,995	10,434
Inventories	4,521	5,526	5,563	9,985	12,471	14,479
ST bank deposits	15,349	16,812	13,495	20,000	25,000	25,000
Financial assets at FVTPL	1,262	781	751	761	771	781
Other current assets	3,808	4,384	5,738	10,554	12,738	14,769
Non-current assets	27,964	29,641	32,970	34,822	33,691	34,691
PP&E	10,607	10,954	11,522	11,411	10,962	10,255
Right-of-use assets	1,955	1,456	1,262	1,087	902	707
Investment in JVs & assos	2,295	2,085	1,963	2,213	2,313	2,413
Intangibles	1,043	4,949	4,610	4,216	3,803	3,371
Other non-current assets	12,064	10,197	13,613	15,895	15,711	17,944
Total assets	71,491	84,163	82,706	114,494	135,863	155,358
		04,100	-	117,707	100,000	100,000
Current liabilities	24,115	36,112	39,865	69,703	85,279	99,032
Short-term borrowings	2,419	3,889	4,609	0	0	0
Account payables	14,223	22,210	23,080	53,919	67,343	78,187
Tax payable	28	6	15	50	50	50
Other current liabilities	6,954	9,640	11,836	15,433	17,613	20,545
Lease liabilities	491	366	324	301	273	249
Non-current liabilities	10,465	11,722	11,566	13,914	15,613	17,103
Long-term borrowings	4,613	5,651	5,665	5,165	5,165	5,165
Deferred income	694	669	823	1,453	1,962	2,552
Other non-current liabilities	5,158	5,403	5,079	7,296	8,486	9,386
Total liabilities	34,580	47,834	51,431	83,616	100,892	116,135
Share capital	0	0	0	0	0	0
		70.050	70,767	71,267	71,667	72,067
Capital surplus	60,697	70,258	10,101	,		
	60,697 (23,787)	(33,930)	(39,492)	(40,389)	(36,696)	(32,844)
Capital surplus Retained earnings Other reserves	(23,787) 0		(39,492) 0			(32,844) 0
Capital surplus Retained earnings	(23,787)	(33,930)	(39,492)	(40,389)	(36,696)	

22 May 2025



					A Wholly Owned 5	A Wholly Owned Subsidiary Of Chiza Merchanis Fa		
CASH FLOW	2022A	2023A	2024A	2025E	2026E	2027E		
YE 31 Dec (RMB mn)								
Operating								
Profit before taxation	(9,114)	(10,339)	(5,860)	(907)	2,631	4,367		
Depreciation & amortization	1,411	2,107	2,573	2,937	3,300	3,585		
Change in working capital	(2,709)	7,352	(443)	18,233	7,870	6,918		
Others	2,181	1,836	1,718	(498)	412	(1,263)		
Net cash from operations	(8,232)	956	(2,012)	19,765	14,213	13,606		
Investing								
Capital expenditure	(4,680)	(2,312)	(2,428)	(2,500)	(2,500)	(2,500)		
Acquisition of subsidiaries/ investments	(619)	(699)	(144)	0	0	0		
Net proceeds from disposal of short-term	9,736	2,837	1,128	(3,528)	(2,000)	0		
investments Others	408	805	189	1,454	1,721	1,936		
Net cash from investing	4,846	631	(1,255)	(4,574)	(2,779)	(564)		
Financing								
Net borrowings	6,119	3,110	1,229	(5,468)	(500)	0		
Proceeds from share issues	(2)	5,020	0	0	0	0		
Others	(113)	(114)	(559)	(231)	30	(34)		
Net cash from financing	6,004	8,015	669	(5,699)	(470)	(34)		
Net change in cash								
Cash at the beginning of the year	11,635	14,714	24,302	21,740	31,232	42,196		
Exchange difference	462	(15)	36	0	0	0		
Cash at the end of the year	14,714	24,302	21,740	31,232	42,196	55,204		
GROWTH	2022A	2023A	2024A	2025E	2026E	2027E		
YE 31 Dec								
Revenue	28.0%	14.2%	33.2%	112.6%	26.0%	16.0%		
Gross profit	17.8%	(85.4%)	1,195.7%	139.0%	31.7%	15.5%		
Operating profit	na	na	na	na	na	176.1%		
EBITDA	na	na	na	na	164.7%	32.6%		
EBIT	na	na	na	na	na	60.6%		
Net profit	na	na	na	na	na	4.3%		
PROFITABILITY	2022A	2023A	2024A	2025E	2026E	2027E		
YE 31 Dec								
Gross profit margin	11.5%	1.5%	14.3%	16.1%	16.8%	16.7%		
Operating margin	(32.4%)	(35.5%)	(16.3%)	(3.0%)	0.8%	1.8%		
EBITDA margin	(28.2%)	(26.0%)	(7.2%)	2.7%	5.6%	6.4%		
Return on equity (ROE)	(23.1%)	(28.3%)	(17.1%)	(2.9%)	11.2%	10.4%		
GEARING/LIQUIDITY/ACTIVITIES	2022A	2023A	2024A	2025E	2026E	2027E		
YE 31 Dec								
Current ratio (x)	1.8	1.5	1.2	1.1	1.2	1.2		
Receivable turnover days	52.6	32.3	21.9	30.0	30.0	30.0		
Inventory turnover days	69.4	66.7	58.0	50.0	50.0	50.0		
Payable turnover days	218.4	268.2	240.6	270.0	270.0	270.0		
VALUATION	2022A	2023A	2024A	2025E	2026E	2027E		
YE 31 Dec								
P/E	ns	ns	ns	ns	37.1	35.8		
P/E (diluted)	ns	ns	ns	ns	37.1	35.8		
P/B	3.3	3.4	4.3	4.4	3.9	3.5		
P/CFPS	ns	129.4	ns	6.9	9.6	10.1		
Div yield (%)	0.0	0.0	0.0	0.0	0.0	0.0		

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.



Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report. Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY	: Stock with potential return of over 15% over next 12 months					
HOLD	: Stock with potential return of +15% to -10% over next 12 months					
SELL	: Stock with potential loss of over 10% over next 12 months					
NOT RATED	: Stock is not rated by CMBIGM					
OUTPERFORM	: Industry expected to outperform the relevant broad market benchmark over next 12 months					
MARKET-PERFORM	: Industry expected to perform in-line with the relevant broad market benchmark over next 12 months					
UNDERPERFORM	: Industry expected to underperform the relevant broad market benchmark over next 12 months					
CMB International Global Markets Limited						

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM. Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time)("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.,) of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investors that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.